In Vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba.
about
Role of isavuconazole in the treatment of invasive fungal infectionsResistance of Asian Cryptococcus neoformans serotype A is confined to few microsatellite genotypesIn vitro antifungal susceptibilities and amplified fragment length polymorphism genotyping of a worldwide collection of 350 clinical, veterinary, and environmental Cryptococcus gattii isolates.Microsatellite typing and susceptibilities of serial Cryptococcus neoformans isolates from Cuban patients with recurrent cryptococcal meningitis.In vitro antifungal activity of isavuconazole against Madurella mycetomatisIsavuconazole: A New Option for the Management of Invasive Fungal Infections.Isavuconazole: a new and promising antifungal triazole for the treatment of invasive fungal infections.A phase 2, randomized, double-blind, multicenter trial to evaluate the safety and efficacy of three dosing regimens of isavuconazole compared with fluconazole in patients with uncomplicated esophageal candidiasisPharmacodynamics of isavuconazole in an Aspergillus fumigatus mouse infection modelCryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for amphotericin B and flucytosine.Extensive genetic diversity within the Dutch clinical Cryptococcus neoformans population.Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole.Evaluation of Etest method for determining isavuconazole MICs against Cryptococcus gattii and Cryptococcus neoformans.In vitro activities of isavuconazole and comparator antifungal agents tested against a global collection of opportunistic yeasts and molds.Efficacy of isavuconazole, voriconazole and fluconazole in temporarily neutropenic murine models of disseminated Candida tropicalis and Candida krusei.Effect of mild and moderate liver disease on the pharmacokinetics of isavuconazole after intravenous and oral administration of a single dose of the prodrug BAL8557.New generation azole antifungals in clinical investigation.New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance.Meningitis caused by Filobasidium uniguttulatum: case report and overview of the literature.Addressing current medical needs in invasive fungal infection prevention and treatment with new antifungal agents, strategies and formulations.Environmental prevalence of Cryptococcus neoformans and Cryptococcus gattii in India: an update.Cryptococcosis: epidemiology, fungal resistance, and new alternatives for treatment.Profile of isavuconazole and its potential in the treatment of severe invasive fungal infectionsCryptococcus and cryptococcosis in Cuba. A minireview.Isavuconazole, a broad-spectrum triazole for the treatment of systemic fungal diseases.The 'cephalosporin era' of triazole therapy: isavuconazole, a welcomed newcomer for the treatment of invasive fungal infections.Isavuconazole: Pharmacology, Pharmacodynamics, and Current Clinical Experience with a New Triazole Antifungal Agent.Isavuconazonium sulfate: a triazole prodrug for invasive fungal infections.Molecular characterisation and antifungal susceptibility of clinical Cryptococcus deuterogattii (AFLP6/VGII) isolates from Southern Brazil.Isavuconazole therapy protects immunosuppressed mice from mucormycosis.In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens.[First description of phenotypic profile and in vitro drug susceptibility of Cryptococcus spp yeast isolated from HIV-positive and HIV-negative patients in State of Mato Grosso].Newer antifungal agents.In vitro antifungal activity of isavuconazole against 345 mucorales isolates collected at study centers in eight countries.Evaluation of antifungal combination against Cryptococcus spp.Isavuconazole and nine comparator antifungal susceptibility profiles for common and uncommon Candida species collected in 2012: application of new CLSI clinical breakpoints and epidemiological cutoff values.Hot topics in antifungal susceptibility testing: A new drug, a bad bug, sweeping caspofungin testing under the rug, and solving the ECV shrug.Molecular epidemiology and antifungal susceptibility of Serbian Cryptococcus neoformans isolates.The status of cryptococcosis in Latin America.
P2860
Q26740837-E24965BD-2410-417E-BE16-4447C6BECB8DQ28731332-584A7BAC-F247-4391-B2CD-FD838B6E28FFQ33696932-E0F3ECE2-F006-4706-80A1-6B7193E89108Q33710112-5EDB97CE-860C-430A-8649-31EC0B50B97FQ34298778-9BF0DCD1-DA87-4142-B931-2C56212F2AFDQ34474946-C9175778-294C-4851-B2F6-E302B3CB1DE3Q34900399-8A4BC716-D8F1-434D-979D-50E878FDFBEDQ35076974-6301105C-17F1-4E8C-85CB-DA747620A217Q35385554-A0D52BD0-1469-45C1-BF65-B4D94F3C5AB6Q36018713-C737AC53-1087-40C4-A10C-1116F1BFC521Q36022995-4A6488C0-3E22-40DC-84B0-BAFDBFD5537FQ36364064-A1284627-B80A-4FF7-8B5E-7E59B0183CFBQ36804054-5DC3A654-4406-49A6-9487-5563B11D1BBEQ37036173-BA28CF4E-FB12-467E-B5ED-AAC32579ED5BQ37291463-65061B6B-67EA-4BAE-B89A-7117D3FAFA52Q37409882-3CE0D1BA-629F-488F-9C2F-2F7352201809Q37579222-0E85D29B-01B8-4F60-AE8E-1F773D37A339Q37608276-F97C894D-49DF-4004-8B41-C02C8E2F8A65Q37897665-7FDA928C-5CDC-48B6-8F95-F1A4B054E414Q37918556-F60753F2-BD64-4694-952B-4002CC4EAA47Q37963502-170FC0F6-3107-4012-8AB3-0F5ABA0162DEQ38154164-F43F77E3-2597-4C98-88A9-F4EFB823BCA5Q38159688-E0DC89DC-535C-44F4-B012-FA48EFBEC586Q38270904-C14879E8-0DD7-4CE1-BA4C-DC0CA51C6695Q38285488-3AEDF115-B499-4C8E-93F8-9454D1071723Q38534865-829A0CD7-6960-45D4-8BBD-C270DD8D18A4Q38644817-58A7790D-4A5B-4B2E-A7DE-9A873D3095F1Q38939506-21DCA17C-9709-423D-80DC-A5437F0C6790Q39064815-CFA792E9-4C6F-4853-A25B-F32AF7046C60Q39684037-E6248B5A-6D64-42F4-953F-BC7B9B071292Q41790396-3815D6D7-3EEC-44BC-B930-4B4AE0A66C04Q43140037-8F13F0B0-A7B9-4FDC-9409-37B0D59CF3A7Q44855715-9D9718C8-690A-482E-B5FB-64889F8E582BQ45238820-620C9765-0801-4957-86AD-5F8F7713A6BFQ46554956-AE6858E8-5F3A-4C46-B681-9479462439F3Q46876288-BA68584D-EC51-4C50-B6CD-9AB3B18C04F7Q53779321-B4C33E29-20F7-4012-BC7D-58D6D2EAD525Q54227412-AB581EF6-BB49-4AB9-B3DE-C064F9FF2EE4Q54237824-E82F78C3-1C5A-4730-BC6F-B83B2C1083D2
P2860
In Vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
In Vitro activity of the new a ...... neoformans isolates from Cuba.
@en
In Vitro activity of the new azole isavuconazole
@nl
type
label
In Vitro activity of the new a ...... neoformans isolates from Cuba.
@en
In Vitro activity of the new azole isavuconazole
@nl
prefLabel
In Vitro activity of the new a ...... neoformans isolates from Cuba.
@en
In Vitro activity of the new azole isavuconazole
@nl
P2093
P2860
P356
P1476
In Vitro activity of the new a ...... neoformans isolates from Cuba.
@en
P2093
Carlos M Fernández
Gerardo F Martínez
Ilse Curfs-Breuker
Jacques F Meis
Maria-Teresa Illnait-Zaragozi
P2860
P304
P356
10.1128/AAC.01384-07
P407
P577
2008-01-22T00:00:00Z